The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...
Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments.
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research ...
In March of this year, ACTO co-founder and CEO Parth Khanna wrote a piece for Pharmaceutical Executive discussing an area where he sees AI making a major impact. According to him, digital health ...
There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the ...
Nate Hill, co-founder & CEO of Strive Pharmacy, argues that a Category one designation for peptides would give physicians a trusted, regulated channel they currently lack. Nate Hill, Co-Founder & CEO ...
The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma ...
GSK intends to move its mRNA seasonal influenza vaccine candidate to a Phase III efficacy trial starting in September. The move is based on presented positive Phase II data for it ...
Pharma has more competitive data than ever — and is still getting surprised. Lifescience Dynamics on why intelligence requires human judgment.
BioNTech and Genentech elect to end their Phase II trial of autogene Cevumeran after DSMB identified a numerical overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results